CAS 1446182-94-0: GDC-0917

CUDC-427 (GDC-0917) is an orally bioactive and pan antagonist of inhibitor of apoptosis proteins(IAPs). CUDC-427 can be used in research on cancers.

CUDC-427 is a small-molecule inhibitor of apoptosis proteins (IAP), which is a synthetic compound sourced from the design and synthesis of targeted anticancer agents. Its primary mode of action involves the selective inhibition of IAPs, particularly cIAP1 and cIAP2. This inhibition leads to the activation of caspases and subsequent induction of apoptosis in cancer cells. CUDC-427 is primarily utilized in research focused on cancer treatment, offering potential therapeutic applications by promoting apoptosis in tumor cells that have developed resistance to other forms of treatment. It is particularly of interest in studies involving malignancies such as breast cancer, ovarian cancer, and various hematological cancers. The compound's ability to sensitize cancer cells to existing treatments makes it a valuable tool in developing combination therapies, enhancing the efficacy of chemotherapeutic agents and potentially improving patient outcomes. Research into CUDC-427 continues to explore its full clinical potential, including its pharmacokinetics, safety profile, and effectiveness across different cancer types.

CUDC-427